Fresh analysis indicates that individuals who come off new slimming jabs like Mounjaro or Wegovy may regain reduced body mass far faster than those who halt traditional lifestyle plans.
Findings released in a prominent health publication demonstrates that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users using these medications should be aware of the potential of quick weight regain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of recovery implies a reversion to original weight within about one and a half years.
Weighing Approaches
The research, which examined dozens of studies involving thousands of patients, compared the effects of the injectable medications with other pills.
Scientists note that people who lose weight through diet and exercise typically see a slower weight regain—approximately 0.1 kg a month—once they finish.
The Reason for the Fast Rebound
Nutrition scientists propose the mechanism of the jabs is key to understanding the amplified rebound.
The injections copy a body's own chemical called GLP-1, which controls hunger.
"Artificially providing the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication leads to appetite is uncontrolled, making overeating much more probable."
An Ongoing Condition?
The NHS suggest the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals contend that, considering the likelihood of weight regain, the treatment is often life-long.
This perspective is echoed by drug manufacturers, who note that the results "emphasize the long-term character of excess weight," akin to managing conditions like hypertension.
User Accounts
People who have discontinued the jabs describe a intense return of appetite.
"I experienced something that goes on and I was suddenly starving," described one woman.
This difficulty is compounded if patients have not established sustainable dietary or behavioural modifications during treatment.
Growing Use
Figures suggest that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow.
- Use is more common among females compared to males.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent solution and long-term success hinges on ongoing behavioural changes.